Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMGEN FIRST YEAR EPOGEN SALES BOOST FY 1990 REVENUES 155% TO $199 MIL.

Executive Summary

Amgen Epogen sales are annualizing at over $200 mil. based on sales of the product in the three months ended March 31. The Thousand Oaks, Calif. biotech firm said its product sales, derived almost entirely from Epogen, were $53.6 mil. in the company's fourth fiscal quarter ended March 31, up from $806,000 for the same period last year. For fiscal 1990, Amgen reported product sales of $152.2 mil., up from $2.7 mil. in fiscal 1989. Although Amgen did not specifically break out Epogen sales, the company's product sales figures indicate that the erythropoietin product generated approximately $150 mil. in sales in the 10 months since its launch. Amgen revenues more than doubled in fiscal 1990 to $199 mil. Fiscal 1989 revenues of $78.1 mil. stemmed primarily from corporate partner revenues of $67.4 mil. and interest income of$7.9 mil. Epogen currently is received by an estimated 55,000 patients with anemia associated with chronic renal failure, representing "over 60% of those dialysis patients eligible for Epogen therapy," Amgen CEO Gordon Binder commented. The company reported a profit for the year of $19.1 mil.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel